Xolair

Xolair Dosage/Direction for Use

omalizumab

Manufacturer:

Novartis

Distributor:

DKSH
Full Prescribing Info
Dosage/Direction for Use
Dosage regimen for allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP): Dosing for asthma and CRSwNP follows the same dosing principles. The appropriate dose and dosing frequency of Xolair for these conditions is determined by baseline immunoglobulin E (IgE) (IU/mL), measured before the start of treatment, and body weight (kg). Prior to initial dosing, patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment. Based on these measurements, 75 to 600 mg of Xolair in 1 to 4 injections may be needed for each administration. See Table 6 for a conversion chart and Tables 7 and 8 for dose determination. For doses of 225, 375 or 525 mg Xolair, 150 mg can be used in combination with Xolair 75 mg.
Patients whose baseline IgE levels or body weight in kilograms are outside the limits of the dosing table should not be given Xolair. (See Table 6.)

Click on icon to see table/diagram/image

Treatment duration, monitoring and dose adjustments: In clinical trials for allergic asthma, there were reductions in asthma exacerbation events and rescue medication use with improvements in symptom scores during the first 16 weeks of treatment. At least 12 weeks of treatment is required to adequately assess whether or not a patient is responding to Xolair.
In clinical trials for CRSwNP, changes in nasal polyps score (NPS) and nasal congestion score (NCS) were observed as early as the first assessment at 4 weeks. The need for continued therapy should be periodically reassessed based upon the patient's disease severity and level of symptom control.
Xolair is intended for long-term treatment. Discontinuation generally results in a return to elevated free IgE levels and associated symptoms.
Total IgE levels are elevated during treatment and remain elevated for up to one year after the discontinuation of treatment. Therefore, re-testing of IgE levels during Xolair treatment cannot be used as a guide for dose determination. Dose determination after treatment interruptions lasting less than one year should be based on serum IgE levels obtained at the initial dose determination. Total serum IgE levels may be re-tested for dose determination if treatment with Xolair has been interrupted for one year or more.
Doses should be adjusted for significant changes in body weight (see Tables 7 and 8).

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Dosage regimen for Chronic Spontaneous Urticaria (CSU): The recommended dose is 300 mg by subcutaneous injection every four weeks. Some patients may achieve control of their symptoms with a dose of 150 mg every four weeks.
Special populations: Renal or hepatic impairment: There have been no studies on the effect of impaired renal or hepatic function on the pharmacokinetics of omalizumab. Because omalizumab clearance at clinical doses is dominated by IgG clearance process, including degradation in the reticular endothelial system (RES) it is unlikely to be altered by renal or hepatic impairment. While no particular dose adjustment is recommended, Xolair should be administered with caution in these patients (see PRECAUTIONS).
Pediatric patients: In allergic asthma, safety and efficacy in patients below the age of 6 have not been established and use of Xolair in such patients is therefore not recommended.
In CRSwNP, safety and efficacy in patients below the age of 18 years have not been established.
In chronic spontaneous urticaria, safety and efficacy in patients below the age of 12 years have not been established.
Geriatric patients (65 years or above): There are limited data available on the use of Xolair in patients 65 years and older but there is no evidence that elderly patients require a different dosage from younger adult patients.
Method of administration: Powder and solvent for solution for injection: For subcutaneous administration only. Xolair must not be administered by the intravenous or intramuscular route.
Doses of more than 150 mg should be divided across two or more injection sites.
There is limited experience with self-administration of Xolair powder and solvent for solution for injection. Therefore treatment with this formulation is intended to be administered by a healthcare professional only.
Full instructions for use are provided in Instructions for Use and Handling under Cautions for Usage.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in